Free Trial Information
BioCentury | Dec 18, 2006
Company News

Kemia management update

Kemia Inc. , San Diego, Calif. Business: Chemistry, Autoimmune Hired: Martin Emanuele as SVP of business development, formerly VP of business development and portfolio management of Avanir Pharmaceuticals WIR Staff autoimmune...
Read More
BioCentury | Aug 28, 2006
Clinical News

KC706: Phase I data

...safe and well tolerated and confirmed the bioavailability of the compound in a capsule formulation. Kemia Inc....
Read More
BioCentury | Aug 28, 2006
Company News

Kemia board of directors update

Kemia Inc. , San Diego, Calif. Business: Autoimmune Appointed: Dan Kisner, a partner at Aberdare Ventures; Wayne Hockmeyer, president of MedImmune Ventures Inc.; and Bonnie Hepburn, former SVP of drug development at Santarus Inc. Resigned: Tamas...
Read More
BioCentury | Aug 28, 2006
Clinical News

KC706: Phase IIa start

...Kemia will start a placebo-controlled, European Phase II trial 150 RA patients next month. Kemia Inc....
Read More
BioCentury | Aug 24, 2006
Financial News

Kemia raises $31 million

...and Texas Pacific Group. Aberdare's Dan Kisner and MedImmune's Wayne Hockmeyer joined Kemia's board. Separately, Kemia...
...studies also confirmed the bioavailability of a capsule formulation to be used in future trials. Kemia...
Read More
BioCentury | Jan 17, 2005
Company News

Kemia management update

Kemia Inc. , San Diego, Calif. Business: Inflammation, Neurology, Cancer Hired: Alison Pilgrim as CMO, formerly CMO at Avera Pharmaceuticals Inc.; and Bryan Jones as VP of business development, formerly associate director of business development at...
Read More
BioCentury | Nov 15, 2004
Emerging Company Profile

Kemia: Allosteric coupling to kinases

...of the highly conserved nature of binding sites across these enzymes. To address this problem, Kemia Inc....
...the regulation of interleukin-1 (IL-1) , tumor necrosis factor (TNF) alpha and other immune responses. Kemia...
...BioCentury, Sept. 22, 2003) . Kemia is in talks to partner this program. In March, Kemia...
Read More
BioCentury | Nov 15, 2004
Emerging Company Profile

Corporate Profile

Kemia Inc. San Diego, Calif. Technology: Small molecule allosteric kinase inhibitors and alpha helix mimetics Disease focus: Inflammation Clinical status: Preclinical Founded: 2002 by Tamas Bartfai, Julius Rebek and Andrew Hamilton Corporate partners: None University...
Read More
BioCentury | Apr 5, 2004
Finance

Ebb & Flow

...company's SDX-105 bendamustine alkylating agent is in Phase II/III testing to treat non-Hodgkin's lymphoma (NHL). Kemia...
Read More
BioCentury | Apr 5, 2004
Company News

Kemia board of directors update

Kemia Inc. , San Diego, Calif. Business: Drug discovery Appointed: Rod Ferguson, partner at JPMorgan Partners WIR Staff...
Read More
Items per page:
1 - 10 of 15
BioCentury | Dec 18, 2006
Company News

Kemia management update

Kemia Inc. , San Diego, Calif. Business: Chemistry, Autoimmune Hired: Martin Emanuele as SVP of business development, formerly VP of business development and portfolio management of Avanir Pharmaceuticals WIR Staff autoimmune...
Read More
BioCentury | Aug 28, 2006
Clinical News

KC706: Phase I data

...safe and well tolerated and confirmed the bioavailability of the compound in a capsule formulation. Kemia Inc....
Read More
BioCentury | Aug 28, 2006
Company News

Kemia board of directors update

Kemia Inc. , San Diego, Calif. Business: Autoimmune Appointed: Dan Kisner, a partner at Aberdare Ventures; Wayne Hockmeyer, president of MedImmune Ventures Inc.; and Bonnie Hepburn, former SVP of drug development at Santarus Inc. Resigned: Tamas...
Read More
BioCentury | Aug 28, 2006
Clinical News

KC706: Phase IIa start

...Kemia will start a placebo-controlled, European Phase II trial 150 RA patients next month. Kemia Inc....
Read More
BioCentury | Aug 24, 2006
Financial News

Kemia raises $31 million

...and Texas Pacific Group. Aberdare's Dan Kisner and MedImmune's Wayne Hockmeyer joined Kemia's board. Separately, Kemia...
...studies also confirmed the bioavailability of a capsule formulation to be used in future trials. Kemia...
Read More
BioCentury | Jan 17, 2005
Company News

Kemia management update

Kemia Inc. , San Diego, Calif. Business: Inflammation, Neurology, Cancer Hired: Alison Pilgrim as CMO, formerly CMO at Avera Pharmaceuticals Inc.; and Bryan Jones as VP of business development, formerly associate director of business development at...
Read More
BioCentury | Nov 15, 2004
Emerging Company Profile

Kemia: Allosteric coupling to kinases

...of the highly conserved nature of binding sites across these enzymes. To address this problem, Kemia Inc....
...the regulation of interleukin-1 (IL-1) , tumor necrosis factor (TNF) alpha and other immune responses. Kemia...
...BioCentury, Sept. 22, 2003) . Kemia is in talks to partner this program. In March, Kemia...
Read More
BioCentury | Nov 15, 2004
Emerging Company Profile

Corporate Profile

Kemia Inc. San Diego, Calif. Technology: Small molecule allosteric kinase inhibitors and alpha helix mimetics Disease focus: Inflammation Clinical status: Preclinical Founded: 2002 by Tamas Bartfai, Julius Rebek and Andrew Hamilton Corporate partners: None University...
Read More
BioCentury | Apr 5, 2004
Finance

Ebb & Flow

...company's SDX-105 bendamustine alkylating agent is in Phase II/III testing to treat non-Hodgkin's lymphoma (NHL). Kemia...
Read More
BioCentury | Apr 5, 2004
Company News

Kemia board of directors update

Kemia Inc. , San Diego, Calif. Business: Drug discovery Appointed: Rod Ferguson, partner at JPMorgan Partners WIR Staff...
Read More
Items per page:
1 - 10 of 15